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The recent surge in research on cannabinoids may have been fueled by changes in
legislation in several jurisdictions, and by approval for the use of cannabinoids for treatment
of some chronic diseases. Endocannabinoids act largely, but not exclusively on
cannabinoid receptors 1 and 2 (CBR1 and CBR2) which are expressed in the bladder
mainly by the urothelium and the axons and endings of motor and sensory neurons. A
growing body of evidence suggests that endocannabinoid system constitutively
downregulates sensory bladder function during urine storage and micturition, under
normal physiological conditions. Similarly, exogenous cannabinoid agonists have
potent modulatory effects, as do inhibitors of endocannabinoid inactivation. Results
suggest a high potential of cannabinoids to therapeutically ameliorate lower urinary
tract symptoms in overactive bladder and painful bladder syndromes. At least part of
this may be mediated via effects on sensory nerves, although actions on efferent nerves
complicate interpretation. The sensory innervation of bladder is complex with at least eight
classes identified. There is a large gap in our knowledge of the effects of endocannabinoids
and synthetic agonists on different classes of bladder sensory neurons. Future studies are
needed to reveal the action of selective cannabinoid receptor 2 agonists and/or
peripherally restricted synthetic cannabinoid receptor 1 agonists on bladder sensory
neurons in animal models of bladder diseases. There is significant potential for these
novel therapeutics which are devoid of central nervous system psychotropic actions, and
which may avoid many of the side effects of current treatments for overactive bladder and
painful bladder syndromes.
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INTRODUCTION
The endocannabinoid system (ECS) consists of several endocannabinoids and their G-protein
coupled receptors (GPCRs) together with synthetizing and degradation enzymes which are present
in nearly every bodily tissue including bladder and dorsal root ganglion (DRG) neurons (Merriam
et al., 2011; Strittmatter et al., 2012; Bakali et al., 2013; Izzo et al., 2015; Hedlund and Gratzke, 2016;
Bjorling and Wang, 2018). The two most-studied endocannabinoids are
N-arachidonoylethanolamine (anandamide; AEA) and 2-arachidonoylglycerol (2-AG) which act
on cannabinoid receptors (CBRs), CBR1 and CBR2. CBR1 is mainly expressed in nervous tissue
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whilst CBR2 is expressed on immune tissue and peripheral
afferent nerves (Rice et al., 2002; Hillsley et al., 2007; Ruggieri,
2011; Cristino et al., 2020). Both AEA and 2-AG act extensively in
the central and peripheral nervous system, affecting pain, mood,
feeding behavior, motivation and inflammation (Cristino et al.,
2014; Vuckovic et al., 2018). However, in addition to activation of
CBR1/CBR2, endocannabinoids and their synthetic analogues
can modulate various ion channels including some transient
receptor potential (TRP) channels, ligand-gated ion channels
and GPCRs (Pertwee, 2010; Christie et al., 2020).
Cannabinoids may also act on so-called atypical or
cannabinoid-like receptors such as GPR55 and peroxisome
proliferator-activated receptors (PPARs) (Bouaboula et al.,
2005; Wrobel et al., 2020).
Cannabinoids have been recently demonstrated to suppress
pain behavior in various rodent models of inflammatory pain,
such as arthritis and inflammatory bowel disease (Romero-
Sandoval et al., 2015; Vuckovic et al., 2018). In the bladder
endocannabinoids likely regulate the activity of sensory
neurons involved in urine storage and micturition (Hedlund,
2014). Further, the ECS may have potential to ameliorate lower
urinary tract symptoms such as urgency and pain associated with
common bladder disorders, including overactive bladder (OAB)
and painful bladder syndromes (PBS) (see recent reviews
Hedlund and Gratzke, 2016; Bjorling and Wang, 2018). This
mini review focuses on recent data revealing the ability of
endocannabinoids to modulate sensory neuron function
regulating urine storage and micturition, and their potential to
treat OAB syndrome and PBS.
EFFECTS OF CANNABINOIDS ON
MICTURITION: POSSIBLE INVOLVEMENT
OF SENSORY NERVES
In the bladder, CBR1 and CBR2 are expressed in urothelial
cells, detrusor muscle and nerve fibres (Hayn et al., 2008;
Gratzke et al., 2009; Bakali et al., 2013). Despite the
expression of CBR1 and CBR2 in the detrusor,
endocanabinoids have little (Saitoh et al., 2007) or no effect
on detrusor muscle itself (Martin et al., 2000; Gratzke et al.,
2009). The role of endocannabinoids in modulating sensory
function in the bladder is supported by the expression of both
CBR1 and CBR2 on the axons in the sub-urothelium and
detrusor muscle (Hayn et al., 2008; Gratzke et al., 2009;
Walczak et al., 2009; Bakali et al., 2013; Kim et al., 2017)
(Figure 1), where they co-localise with established sensory
markers such as calcitonin gene-related peptide (CGRP),
TRP vanilloid 1 (TRPV1) and P2X3 purinoreceptors
(Gratzke et al., 2009; Walczak et al., 2009; Izzo et al., 2015).
FIGURE 1 | Potential targets of endocannabinoids on bladder sensory nerve endings. At least eight classes of bladder afferents within five major types can be
distinguished in the lumbar splanchnic and sacral pelvic neural pathways. These include low-threshold non-encoding and encodings muscular afferents, muscular-
mucosal afferents, high- and low-responding mucosal afferents (largely in the lumbosacral DRG innervating evenly all areas of the bladder) and high-threshold muscular
and vascular afferents and mechano-insensitive silent afferents (predominantly in the thoracolumbar DRG innervating the base of the bladder) (Xu and Gebhart,
2008; de Groat et al., 2015; Guo et al., 2020). Only five types of bladder afferents illustrated at the figure. These classes/types of afferents have receptive fields with
specific structures and locations within the bladder wall and possess specific combinations of ion channels and receptors which regulate their excitability (Zagorodnyuk
et al., 2010; Merrill et al., 2016; Grundy et al., 2019a). Both low- and high-threshold afferents may undergo sensitisation as a result of bladder inflammation and thus
transmit nociceptive information (Roppolo et al., 2005; Walczak and Cervero, 2011; Yoshimura et al., 2014; Zagorodnyuk et al., 2019). Pelvic low-threshold non-
encoding muscular and muscular-mucosal afferents signal mechanical information about micturition and non-painful sensation from the bladder. Low-threshold
encoding afferents, high-threshold muscular and vascular afferents, mucosal high-responding and silent afferents probably all detect noxious mechanical and chemical
stimuli. These then contribute to pathological states, which result in lower urinary tract symptoms. Potential targets of endocannabinoids in the bladder include CBR1 on
the high threshold stretch-sensitive afferents (Walczak and Cervero, 2011); CBR1/CBR2 on the low-threshold distension-sensitive afferents (Aizawa et al., 2014) and
CBR2 on the mucosal high-responding afferents (Christie and Zagorodnyuk, 2021). More functional studies are imperative to fully characterise CBR types and their
intracellular transduction mechanisms in different classes of bladder afferents.
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Cystometry studies demonstrate that endocannabinoids can
modulate micturition intervals and threshold pressure, both of
which may reflect bladder afferent function. However, their role
in healthy bladders is inconsistent, most likely due to differences
in particular drug used (e.g. endocannabinoids and their synthetic
analogues versus drugs modifying endogenous level of
endocannabinoids), route of administration and/or species
studied (see Table 1). For example, both intravesical and
serosal application of AEA dose-dependently decreased
micturition interval in anaesthetised rats via TRPV1; an effect
blocked by a CBR1 antagonist (Dinis et al., 2004). Conversely, in
anaesthetised rats, intravenous infusion of an AEA transport
inhibitor (VDM11), which increases tissue concentrations of
AEA, increased micturition interval and threshold pressure.
This effect was blocked by CBR1 antagonist (AM251) but not
CBR2 antagonist (AM630) (Honda et al., 2016). These
discrepancies are likely from different administration routes of
AEA and VDM11. This may lead to preferential action of AEA on
different classes of bladder afferents with different profile of
expression of CBR1/CBR2 and/or TRPV1. In conscious rats,
intravesical or intravenous administration of the FAAH
inhibitor, oleoyl ethyl amide inhibited bladder reflex activity,
similar to VDM11. However, these effects were abolished by a
CBR2 antagonist (SR144528), whilst a CBR1 antagonist
(rimonabant) only reduced effects on threshold pressure
(Strittmatter et al., 2012). This agrees with the effect of
selective CBR2 agonist, cannabinor which increased
micturition intervals and volume when applied intravenously.
This indicates involvement of CBR2 in sensory function since
cannabinor did not affect nerve-mediated contractions in the
isolated rat bladder strips (Gratzke et al., 2009; Gratzke et al.,
2010). However, it is unclear which particular class(es) of bladder
afferents are responsible for these effects. It is worth mentioning
that in rat and human bladders, CBR1 and CBR2 are
also expressed in motor cholinergic bladder nerves (Gratzke
et al., 2010; Bakali et al., 2013). Further, endocannabinoids
TABLE 1 | Cannabinoid drugs and their effects on sensory neurons and bladder function.
Drug Target Off
Target




CBR1 Mouse LPS cystitis
ex vivo
2.5 mg/kg Intraperitoneal No effect on bladder contractions Tambaro et al.
(2014)
Mouse in vivo 100 µM Intravesical ↓Bladder activity induced by NGF Wang et al. (2015a)
Anandamide CBR1/
CBR2




↓Micturition interval via TRPV1 and
CBR1 in cystitis
Dinis et al. (2004)
Rat in vivo 100 µM Intravesical ↓Micturition interval Gratzke et al.
(2009)







Rat ex vivo 75 nM Organ bath ↓ATP and capsaicin induced CGRP
release via CBR1 and CBR2
Hyan et al. (2008)
AZ12646915 CBR1/
CBR2
Mouse ex vivo 100 µM Intravesical ↓Distension-induced firing of high





100 µM Intravesical ↓Sensitisation of stretch-sensitive
afferents in cystitis via CBR1
Walczak and
Cervero, (2011)










Rat in control and
acetic acid OAB in
vivo
0.005 mg/kg Intravesical ↑Micturition interval and bladder
capacity in OAB via CBR1 and CBR2
Bakali et al.
(2016a)
GP1a CBR2 Mice acrolein
cystitis in vivo
10 mg/kg Intraperitoneally ↓Decreased mechanical sensitivity in
cystitis via CBR2
Wang et al. (2014)
JWH-015 CBR2 Mice LPS cystitis
ex vivo
5 mg/kg Intraperitoneal ↓ Bladder inflammation and
contractions in cystitis via CBR2
Tambaro et al.
(2014)
JWH-133 CBR2 Mouse CYP
cystitis in vivo
1 mg/kg Intraperitoneal ↓Bladder inflammation ↓Mechanical
sensitivity via CBR2
Liu et al. (2020)
O-1602 GPR55 GPR18 Rat retinyl acetate
OAB in vivo
0.25 mg/kg Intraarterial ↓Detrusor activity in OAB Wrobel et al.
(2020)
Oleoyl ethyl amide FAAH Rat in vivo 0.3 mg/kg Intravenous ↓Bladder reflex activity via CBR2 Strittmatter et al.
(2012)
URB937 FAAH Rat in vivo 1 mg/kg Intravenous ↓Distension-induced firing and PGE2
sensitisation of C-fibers via CBR1 and
CBR2
Aizawa et al. (2014)
Aizawa et al. (2016)
VDMI AEA
transporter
Rat in vivo 3–10 mg/kg Intravenous ↑Micturition interval ↑Bladder
capacity via CBR1
Honda et al. (2016)
Abbreviations: CYP – cyclophosphamide, NGF – nerve growth factor, LPS – lipopolysaccharide, FAAH – fatty acid amide hydrolase, AEA – anandamide, CBR – cannabinoid receptors.
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pre-synaptically modulate contractility of isolated bladder
preparations mainly via CBR1 in species-dependent manner
(Martin et al., 2000; Gratzke et al., 2009). Thus, the direct
action of endocannabinoids on efferent nerves means that
effects on sensory nerves cannot be identified with certainty
from cystometry studies. Rather, direct studies of cannabinoid
action on bladder afferent firing may be required.
SENSORY INNERVATION OF THE
BLADDER
Spinal sensory neurons innervating the bladder play a key role
mediating both storage and micturition. They are responsible for
bladder sensations, ranging from physiological sensation of filling
and fullness through to lower urinary tract symptoms such as
urgency and pain (de Groat and Yoshimura, 2009; Merrill et al.,
2016). The bladder has a dual sensory innervation, with afferents
projecting via sacral pelvic nerves (cell bodies from L5 to S2 DRG)
and to lesser extent via lumbar splanchnic nerves (cell bodies
from T12 to L2) (Keast and De Groat, 1992; Nandigama et al.,
2010). Thinly myelinated Aδ fibre afferents in the pelvic-sacral
nerves are essential for the sensation of filling and initiation of the
micturition reflex (Fowler et al., 2008). In cats, C-fibre bladder
afferents are normally not mechano-sensitive but can be activated
by noxious stimuli or acquire mechano-sensitivity during
inflammation (Janig and Koltzenburg, 1990). However, in rats
and mice, both pelvic Aδ fibre and C-fibre afferents mostly
express CGRP and TRPV1 and the majority are mechano-
sensitive (Shea et al., 2000; de Groat et al., 2015; Kadekawa
et al., 2017).
Sensation from the bladder involves at least eight classes of
bladder afferents within five major types of afferents (Figure 1).
Low-threshold muscular afferents are “in series tension
receptors” which respond to bladder distension and
contraction and have receptive fields in the detrusor (Shea
et al., 2000; Zagorodnyuk et al., 2007). They comprise two
classes: 1) narrow range afferents, whose firing plateaus at
high distension (“non-encoding muscular afferents”) and 2)
wide dynamic range afferents (“encoding muscular afferents”),
which continue to increase firing across the full range of
distension including noxious one (Xu and Gebhart, 2008; Mills
et al., 2020). In guinea pigs, muscular afferents are not CGRP-
immunoreactive and are unresponsive to capsaicin, a TRPV1
agonist (Zagorodnyuk et al., 2010). However, in mice, most low-
threshold stretch-sensitive afferents are capsaicin-sensitive (Daly
et al., 2007). Another type of low-threshold afferent,
muscular–mucosal (or muscular–urothelial) afferents are
sensitive to both low amplitude stretches and to light mucosal
stroking (Zagorodnyuk et al., 2007; Xu and Gebhart, 2008). In
contrast to muscular afferents, these afferents are also sensitive to
the chemical composition of urine. They are likely to have
receptive fields in both the detrusor and in the lamina propria
(Zagorodnyuk et al., 2009).
CGRP- and capsaicin-immunoreactive fibres form a dense
plexus beneath the urothelium (Fowler et al., 2008; Zagorodnyuk
et al., 2010). Most of these belong to stretch-insensitive mucosal
afferents which can be activated by light mucosal stroking and by
chemical stimuli (Zagorodnyuk et al., 2007; Xu and Gebhart,
2008). Their receptive fields consist of simple endings in the
lamina propria, close to urothelial cells (Zagorodnyuk et al., 2010;
Spencer et al., 2018). Mucosal afferents respond to numerous
factors released from urothelial cells, including adenosine
triphosphate, nitrogen oxide, and prostaglandins. These
mediators are released in response to chemical, thermal and
mechanical stimuli (Birder and Andersson, 2013). Two classes
of mucosal mechanoreceptors have been distinguished in the
guinea pig bladder; 1) capsaicin-sensitive mucosal high-
responding afferents, which are activated by a variety of
noxious stimuli and 2) mucosal low-responding afferents
which respond weakly to mucosal stroking, but may be
activated by hypertonic stimuli (Zagorodnyuk et al., 2007).
In many in vivo and ex vivo studies, high threshold
(>15 mmHg or >20 g load) stretch-sensitive mechanoreceptors
have been distinguished in the bladder (Sengupta and Gebhart,
1994; Zagorodnyuk et al., 2007; Xu and Gebhart, 2008; Grundy
et al., 2019b). They are also activated by blunt probes or stiff von
Frey hairs, but not by light mucosal stroking (Xu and Gebhart,
2008; Song et al., 2009). High-threshold afferents probably
represent a heterogenous group of mechanoreceptors. Some
have endings in the detrusor (high threshold muscular
afferents) (Zagorodnyuk et al., 2010) while high-threshold
“vascular afferents”—have receptive fields associated with
blood vessels in the suburothelium (Song et al., 2009), similar
to intramural “vascular” mechanoreceptors (previously called
“serosal” afferents), found in the intestine (Brookes et al.,
2013). Most of the high-threshold afferents in the bladder are
capsaicin-sensitive (Nicholas et al., 2017; Zagorodnyuk et al.,
2019). In addition, a significant group of bladder afferents (up to
30%) do not to respond to any level of distension and therefore
have been called “silent afferents” or “mechano-insensitive
afferents” (Janig and Koltzenburg, 1990; McMahon et al.,
1995; Guo et al., 2020). During acute inflammation some of
these become spontaneously active and mechanosensitive and
may contribute to acute and chronic pain states in cystitis
(McMahon et al., 1995; de Groat et al., 2015).
DIRECT EFFECT OF CANNABINOIDS ON
THE BLADDER AFFERENTS
To date, relatively few studies have investigated the direct effect of
cannabinoids on bladder afferents (Table 1). The non-selective
CBR1/CBR2 agonist AZ12646915 reduces distension-evoked
firing of high-threshold pelvic afferents in mouse bladder via
CBR1 (Walczak et al., 2009). A non-selective cannabinoid
agonist, ajulemic acid, reduces ATP- and capsaicin-evoked
release of CGRP in the rat bladder; an effect reversed by both
CB1 and CB2 antagonists, AM252 and AM630 (Hayn et al.,
2008). Intravenous administration of a selective, peripherally
restricted fatty acid amide hydrolase (FAAH) inhibitor,
URB937, increases the tissue concentration of
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endocannabinoids and simultaneously decreases distension-
induced activity of Aδ and C-fibers in in vivo studies in rats.
This effect is abolished by CBR1 and CBR2 antagonism,
rimonabant and SR144528 (Aizawa et al., 2014). URB937 also
reduces the sensitisation of C-fibers induced by intravesical
administration of PGE2 (Aizawa et al., 2016). It is important
to note that endogenous cannabinoids can constitutively
downregulate bladder sensory neuron function in rats and
mice since both CBR1 (rimonabant and AM251) and CBR2
antagonists (SR144528) alone significantly increase distension-
induced firing (Walczak and Cervero, 2011; Aizawa et al., 2014).
Distension-induced afferents studied in whole bladder ex vivo
(Walczak et al., 2009; Walczak and Cervero, 2011) or in vivo
(Aizawa et al., 2014) likely include both low- and high-threshold
muscular and muscular-mucosal classes of bladder afferents.
However, in the guinea pigs, the stable analogue of
anandamide, methanandamide (up to 30 µM) did not affect
stretch-induced firing of muscular-mucosal afferents (Christie
and Zagorodnyuk, 2021). The highly selective CBR2 agonist, 4-
quinolone-3-carboxamide, inhibits the mechanosensitivity of
high-responding mucosal afferents (Christie and Zagorodnyuk,
2021). CBR2 antagonist, SR144528 on its own did not
significantly change stroking-induced firing of mucosal
afferents. Methanandamide potentiated the mechanosensitivity
of mucosal afferents to stroking via TRPV1. In the presence of
TRPV1 antagonist (capsazepine), its effect switched to inhibitory
(Christie and Zagorodnyuk, 2021). It is still unclear whether
excitatory and inhibitory effects of methanandamide involved the
same or different CBRs. Overall, these studies indicate potent and
species-dependent modulatory effects of endogenous and
exogenous cannabinoids on bladder afferents which occurs via
CBR1 and CBR2 (see Figure 1). Undoubtedly, more studies are
needed to fully elucidate complex direct effects of
endocannabinoids and their synthetic agonists on different
classes of bladder afferents.
CANNABINOIDS AND OVERACTIVE
BLADDER
In humans with idiopathic detrusor overactivity (DO), the
density of CBR1 on nerve fibres in the suburothelium and
detrusor is increased (Mukerji et al., 2010). However, in
detrusor sections from DO patients, assessing CBRs in entire
detrusor section rather than focusing on nerve fibres, both CBR1
and CBR2 mRNAs and general immunohistochemical staining
were increased in the mucosa, but decreased in the detrusor
(Bakali et al., 2016b). Experimental obstruction-induced DO in
rats is associated with increases in CBR1 expression in the
urothelium, detrusor and sacral spinal cord, with no changes
in CBR2 (Fullhase et al., 2016; Kim et al., 2017). This highlights
difficulties in translating the data obtained in animal models to
humans. The effects of endocannabinoids in animal models of
OAB are summarised in Table 1. Given the presence of both
CBR1 and CBR2 on nerve fibres within the bladder wall and
relatively modest effects of CBR activation on bladder motor
function, these effects on DO may be mediated by cannabinoid
agonists acting on afferent fibres via CBR1 and CBR2. However,
secondary effects via urothelial and interstitial cells cannot be
ruled out. Recently, evidence has suggested that GPR55, a possible
third CBR, may also be a potential target for treatment of
overactive bladder since the GPR55 agonist O-1602
significantly reduces DO in rats (Wrobel et al., 2020).
CANNABINOIDS AND CYSTITIS
In patients with PBS, the expression of CBR1 in suburothelial, but
not detrusor nerve fibres is significantly increased (Mukerji et al.,
2010). CBR2mRNA, but not CBR1mRNA, increased in acrolein-
induced cystitis in rats (Merriam et al., 2008) and
lipopolysaccharide (LPS)-induced cystitis in mice (Tambaro
et al., 2014). However, in acrolein-induced cystitis in mice,
there was no changes in CBR2 expression (Wang et al., 2014).
No changes in the expression of CBR2 were reported in themouse
bladder in cyclophosphamide-induced cystitis (Liu et al., 2020).
These discrepancies may be due to species differences and/or the
method of induction of cystitis.
AEA levels in rat, but not mouse bladder are increased during
bladder inflammation (Dinis et al., 2004; Merriam et al., 2011;
Wang et al., 2015b; Bjorling and Wang, 2018). Importantly, the
non-selective CBR1/CBR2 agonist AZ12646915 reverses the
sensitisation of stretch-sensitive afferents in
cyclophosphamide-induced cystitis (Walczak and Cervero,
2011). CBR1 on high threshold stretch-sensitive afferents is
likely the target of this agonist (Figure 1). The selective CBR1
agonist, arachidonyl-2’-chloroethylamide (ACEA), inhibits the
increased bladder activity induced by nerve growth factor (NGF)
(Wang et al., 2015a). Further, increasing AEA levels by inhibiting
FAAH (Merriam et al., 2011) or using a FAAH knockout (Wang
et al., 2015b), decreased pain behaviour and bladder
hypersensitivity in rats and mice.
It is important to note that endocannabinoids such as AEA do
not only act via CBR1 and CBR2 but can also activate TRPV1
channels, which are pro-nociceptive in the bladder and other
tissues (Charrua et al., 2007; Marrone et al., 2017). Indeed, AEA,
via activation of TRPV1, contributes to hyperreflexia and
hyperalgesia during cyclophosphamide-induced cystitis (Dinis
et al., 2004). Therefore, the strategy to increase the level of
endogenous cannabinoids appears less attractive since the
action of endocannabinoids is complicated by off-target effects
on ligand and voltage-gated channels. Further, pharmacological
inhibition of FAAH in humans demonstrated low efficacy in
reducing chronic pain and had adverse side effects (Feldwisch-
Drentrup, 2017; Vuckovic et al., 2018).
Animal models suggest that CBR2 may be a potential target to
ameliorate pain and bladder inflammation in cystitis. Selective
CBR2 agonists (JWH015, JWH133 and GP1a) reduce the
inflammation, pain behavior, and urinary frequency associated
with cystitis (Tambaro et al., 2014; Wang et al., 2014; Liu et al.,
2020). Whether this is due to reduced inflammation or direct
effects on bladder afferents, or both is not clear. A growing body
of evidence indicates that CBR2 activation decreases infiltration
of inflammatory cells and markers such as leukocytes,
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interleukins, and tissues necrosis factors in cystitis (Rice et al.,
2002; Tambaro et al., 2014; Wang et al., 2014; Liu et al., 2020).
This suggests that a reduction in inflammation itself by CBR2
activation may be one of the main causes for a reduction in
inflammatory hyperalgesia.
Chemically related to AEA, palmitoylethanolamide (PEA) is a
ligand for PPARα (Lo Verme et al., 2005). PEA has significant
analgesic effects (Keppel Hesselink and Kopsky, 2015) and,
similar to AEA, PEA levels are elevated in cystitis in rats
(Merriam et al., 2011; Pessina et al., 2015). PEA may
potentiate effects of endocannabinnoids on the CBRs through
an “entourage” effect (Pessina et al., 2015). Exogenous PEA
reduces viscero-visceral hyperreflexia induced by NGF, via an
effect on CBR2 (Farquhar-Smith et al., 2002). However,
exogenous PEA may also attenuate bladder pain and
inflammation by enhancing the effect of anandamide on CBR1
(Pessina et al., 2015).
Thus, these data demonstrated that both CBR1 and CBR2
agonists are effective in decreasing pain behaviour and bladder
hypersensitivity in animal models of PBS. The exact mechanisms
of these effects remain to be established. It is still unclear which
specific class(es) of bladder afferents contribute the most to
analgesic effect of endocannabinoids as well as exact role of
immune, urothelial, and other cells within the bladder wall.
CONCLUSION
Despite some discrepancies in the expression of CBR1/CBR2
and the effects of exogenous and endogenous cannabinoids on
sensory neurons and micturition in naive bladders and in
animal models of OAB and PBS, preclinical research has
identified the significant potential of cannabinoids as novel
treatments for common bladder disorders. CBR2 agonists and/
or peripherally restricted synthetic CBR1 agonists may
significantly ameliorate lower urinary tract signs/symptoms
in animal models of OAB and PBS. They are likely to lack the
CNS psychotropic actions and sides effects of current
treatments. Use of FAAH and other inhibitors to elevate the
level of endogenous endocannabinoids currently appears less
attractive since the action of endocannabinoids is complicated
by off-target effects on ligand and voltage-gated channels, low
efficacy, and possible side effects. This review has highlighted
the paucity of basic research studies evaluating the direct
effects of cannabinoids on the bladder sensory neurons. At
least eight classes of bladder afferents, with very different roles
in sensory signaling have been identified to date. To design
better strategies for the treatment of lower urinary tract
symptoms, further basic research studies are needed to
elucidate the mechanisms of direct effects of
endocannabinoids and their synthetic agonists on different
classes of bladder afferents. This will help establish the precise
mechanisms of their analgesic and anti-inflammatory actions
in models of bladder diseases.
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